135 related articles for article (PubMed ID: 8737633)
1. Dialysis clearance of buflomedil in hemodialysed patients.
Rey E; Moynot A; d'Athis P; Pello JY; Maurel A; Frydman MO; Buisson C; Olive G
Arzneimittelforschung; 1996 May; 46(5):492-5. PubMed ID: 8737633
[TBL] [Abstract][Full Text] [Related]
2. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
Brandi L
Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics of buflomedil after intravenous administration in patients with chronic renal failure.
Rey E; d'Athis P; Richard MO; Fillastre JP; Olive G
Int J Clin Pharmacol Ther Toxicol; 1984 Dec; 22(12):648-52. PubMed ID: 6526539
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics of buflomedil after various dosage forms.
Zecca L; Ferrario P; Pirola R; Reina L; Zambotti F; Zonta N; Lepore AM; Scaglione F; Fraschini F
Arzneimittelforschung; 1989 Apr; 39(4):518-9. PubMed ID: 2751740
[TBL] [Abstract][Full Text] [Related]
5. [Treatment of circulatory insufficiency with buflomedil chlorhydrate in chronic hemodialysis patients].
Montemurro NE; Damiano M
Clin Ter; 1986 Mar; 116(6):485-9. PubMed ID: 3720235
[No Abstract] [Full Text] [Related]
6. A placebo-controlled study of the effects of intravenous Buflomedil on foot skin microcirculation in patients with severe intermittent claudication.
Van den Brande P; Maurel A
Angiology; 1998 Feb; 49(2):105-14. PubMed ID: 9482510
[TBL] [Abstract][Full Text] [Related]
7. The value of population pharmacokinetics and simulation for postmarketing safety evaluation of dosing guidelines for drugs with a narrow therapeutic index: buflomedil as a case study.
Bourguignon L; Ducher M; Matanza D; Bleyzac N; Uhart M; Odouard E; Maire P; Goutelle S
Fundam Clin Pharmacol; 2012 Apr; 26(2):279-85. PubMed ID: 22004557
[TBL] [Abstract][Full Text] [Related]
8. [Effect of buflomedil perfusion on peripheral tissue oxygenation during transluminal angioplasty in patients with advanced arteriopathy of the lower limbs].
Joffre F; Meites G; Rousseau H; Staffin C; Allaert FA; Pelat P
Ann Radiol (Paris); 1994; 37(3):239-44. PubMed ID: 8092756
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics of dyphylline elimination by uremic patients.
Lee CC; Wang LH; Majeske BL; Marbury TC
J Pharmacol Exp Ther; 1981 May; 217(2):340-4. PubMed ID: 7229976
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics of buflomedil after intravenous and oral administration.
Rey E; Barrier G; d'Athis P; de Lauture D; Richard MO; Lirzin JP; Sureau C; Olive G
Int J Clin Pharmacol Ther Toxicol; 1980 Oct; 18(10):437-41. PubMed ID: 7203720
[TBL] [Abstract][Full Text] [Related]
11. Oral buflomedil in the prevention of cardiovascular events in patients with peripheral arterial obstructive disease: a randomized, placebo-controlled, 4-year study.
; Leizorovicz A; Becker F
Circulation; 2008 Feb; 117(6):816-22. PubMed ID: 18212283
[TBL] [Abstract][Full Text] [Related]
12. Comparison of temsirolimus pharmacokinetics in patients with renal cell carcinoma not receiving dialysis and those receiving hemodialysis: a case series.
Lunardi G; Armirotti A; Nicodemo M; Cavallini L; Damonte G; Vannozzi MO; Venturini M
Clin Ther; 2009 Aug; 31(8):1812-9. PubMed ID: 19808140
[TBL] [Abstract][Full Text] [Related]
13. Clinical and hemorheological effects of buflomedil in diabetic subjects with intermittent claudication.
Diamantopoulos EJ; Grigoriadou M; Ifanti G; Raptis SA
Int Angiol; 2001 Dec; 20(4):337-44. PubMed ID: 11782701
[TBL] [Abstract][Full Text] [Related]
14. Buflomedil kinetics in patients with liver disease.
Rey E; D'Athis P; Richard MO; Guerre J; Dorfman P; Bercoff E; Olive G
Int J Clin Pharmacol Ther Toxicol; 1986 Aug; 24(8):408-14. PubMed ID: 3759277
[TBL] [Abstract][Full Text] [Related]
15. Clearance of vancomycin during high-efficiency hemodialysis.
Klansuwan N; Ratanajamit C; Kasiwong S; Wangsiripaisan A
J Med Assoc Thai; 2006 Jul; 89(7):986-91. PubMed ID: 16881431
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics of vancomycin when administered during high flux hemodialysis.
Foote EF; Dreitlein WB; Steward CA; Kapoian T; Walker JA; Sherman RA
Clin Nephrol; 1998 Jul; 50(1):51-5. PubMed ID: 9710347
[TBL] [Abstract][Full Text] [Related]
17. [The treatment of hyperhomocysteinemia in patients on dialysis: folic acid or the high-flow polysulphonic membrane?].
Lovcić V; Kes P; Zeljko R; Kusec V
Acta Med Croatica; 2006 Jun; 60(3):201-8. PubMed ID: 16933832
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics of L-carnitine in patients with end-stage renal disease undergoing long-term hemodialysis.
Evans AM; Faull R; Fornasini G; Lemanowicz EF; Longo A; Pace S; Nation RL
Clin Pharmacol Ther; 2000 Sep; 68(3):238-49. PubMed ID: 11014405
[TBL] [Abstract][Full Text] [Related]
19. Improvement of microcirculation abnormalities in sickle cell patients upon buflomedil treatment.
Bachir D; Maurel A; Beuzard Y; Razavian M; Kraiem A; Portos JL; Galacteros F
Microvasc Res; 1993 Nov; 46(3):359-73. PubMed ID: 8121319
[TBL] [Abstract][Full Text] [Related]
20. Disposition of didanosine in HIV-seropositive patients with normal renal function or chronic renal failure: influence of hemodialysis and continuous ambulatory peritoneal dialysis.
Knupp CA; Hak LJ; Coakley DF; Falk RJ; Wagner BE; Raasch RH; van der Horst CM; Kaul S; Barbhaiya RH; Dukes GE
Clin Pharmacol Ther; 1996 Nov; 60(5):535-42. PubMed ID: 8941026
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
